


THE EVOLUTION OF HR+/HER2-
EARLY BREAST CANCER CLINICAL PRACTICE
**Broadening the Impact of
CDK4/6 Inhibitors**



Sunday,
15 September 2024



13:00–14:30 CEST



Salamanca Auditorium,
Hall 5, Fira Barcelona Gran Via,
Barcelona, Spain

FACULTY



Dr César A. Rodríguez
Chair

Head of Unit, Medical Oncology Department
Associate Professor
University Hospital of Salamanca-IBSAL
Salamanca, Spain



Dr Peter A. Fasching

Head, Breast Cancer Center
Full Professor of Translational Medicine
University Hospital Erlangen
Comprehensive Cancer Center Erlangen-EMN,
Erlangen, Germany



Dr Sara M. Tolaney

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA, USA

AGENDA

- Welcome and Introduction
- Risk of Recurrence in Patients with HR+/HER2- Early Breast Cancer
- Efficacy of CDK4/6 inhibitors in Patients with HR+/HER2- Early Breast Cancer
- Patient Management Considerations in HR+/HER2- Early Breast Cancer
- Live Q&A and Closing

This symposium is organized and funded by Novartis in the context of ESMO 2024, in Spain.

This scientific program and/or material was developed for use outside of the US, intended for non-US HCPs, and is to be used in accordance with local laws and regulations. The aim of this medical symposium is scientific, educational and not promotional. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country. This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.